Myriad Genetics Inc at Morgan Stanley Global Healthcare Conference Transcript
Hey, guys. Good afternoon. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at Morgan Stanley. Before we begin, I would like to remind our listeners and folks in the room for -- of the important disclosure information can be found at morganstanley.com/researchdisclosures. And if you have any questions on those, you can chat to a salesperson. It's my pleasure today to host Myriad Genomics -- Genetics, sorry. I'm speaking on behalf of the company. I have Paul Diaz, CEO. Thank you so much, Paul, for coming in.
Questions & Answers
Maybe to start Myriad has come a long way since where the company was back in 2019. Just bring us a picture for what the asset looked like when you got there 3 years ago. What's changed since? And what sort of stays the same?
Well, from day
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |